Physician profile
David W Law
NPI 1760475131
$9,083.72
in general payments reported to CMS, 2019-2025
46 companies · $2,233 in 2025
The $2,233 reported for 2025 was more than what 82% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,605 · 2020: $520 · 2021: $737 · 2022: $1,402 · 2023: $1,126 · 2024: $1,461 · 2025: $2,233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,704 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,704.23 |
| Education | $115.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $1,018.25 | 2019-2025 | Provenge |
| Antares Pharma, INC. | $930.51 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Janssen Biotech, INC. | $876.34 | 2019-2025 | Erleada, Akeega |
| Astellas Pharma US INC | $688.60 | 2019-2025 | Xtandi, Veozah |
| Pfizer INC. | $597.71 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $400.95 | 2023-2025 | Orgovyx, Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $322.15 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $293.87 | 2019-2025 | Erleada, Pipeline |
| Merck Sharp & Dohme LLC | $292.79 | 2020-2025 | Keytruda, Lynparza |
| Tolmar, INC. | $250.70 | 2023-2025 | Eligard, Jatenzo |
| Allergan, INC. | $202.23 | 2019-2022 | |
| Axonics, INC. | $200.07 | 2021-2024 | Axonics |
| Tolmar Pharmaceuticals, INC. | $181.94 | 2019-2022 | |
| Abbvie INC. | $175.59 | 2022-2025 | |
| Blue Earth Diagnostics | $173.24 | 2019-2025 | Posluma |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $167.09 | 2019 | |
| Novartis Pharmaceuticals Corporation | $165.94 | 2022-2025 | |
| Teleflex LLC | $164.39 | 2024-2025 | Urolift, Barrigel |
| Biotissue Holdings INC. | $157.81 | 2025 | |
| Verity Pharmaceuticals INC. | $156.87 | 2025 | Tlando, Trelstar |
| Myriad Genetic Laboratories, INC. | $152.20 | 2021-2025 | Prolaris, Myrisk |
| Boston Scientific Corporation | $148.76 | 2019-2025 | Ams 700, Ams 800 Artificial Urinary Sphincter, Axonics |
| Coloplast Corp | $143.99 | 2022-2025 | Speedicath |
| Astrazeneca Pharmaceuticals LP | $137.76 | 2022-2025 | Lynparza, Imfinzi, Evusheld |
| Laborie Medical Technologies Corp. | $123.84 | 2024-2025 | Optilume Bph Drug Coated Balloon Catheter |
| Olympus America INC. | $103.23 | 2019-2025 | Itind System, Bovie |
| Urovant Sciences INC | $99.78 | 2022 | |
| Medtronic, INC. | $86.32 | 2023-2025 | Interstim |
| 180 Medical, INC. | $79.61 | 2022-2024 | |
| Halozyme INC | $65.73 | 2023 | |
| Sun Pharmaceutical Industries INC. | $58.01 | 2024 | |
| Amgen INC. | $54.02 | 2019-2022 | |
| Urogen Pharma, INC. | $46.58 | 2024-2025 | |
| Clarus Therapeutics INC. | $44.34 | 2021 | |
| Myovant Sciences INC. | $41.14 | 2021-2022 | |
| Travere Therapeutics, INC. | $39.98 | 2021 | |
| Immunitybio, INC. | $37.32 | 2024-2025 | |
| Accord Healthcare, INC. | $33.85 | 2024-2025 | |
| Endo Pharmaceuticals INC. | $32.30 | 2021-2022 | |
| Photocure INC | $29.67 | 2023-2025 | Cysview |
| Angiodynamics, INC. | $23.52 | 2025 | Nanoknife |
| Procept Biorobotics Corporation | $19.37 | 2022 | |
| Tempus Ai, INC | $18.13 | 2024 | |
| Amag Pharmaceuticals, INC. | $17.78 | 2019 | |
| Avation Medical, INC. | $15.37 | 2025 | Vivally System |
| Ambu INC. | $14.08 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Law listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.